Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of May 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate a press release dated May 22, 2018, by reference into the company's Registration Statements on Forms F-3 and S-8.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quarterly results summary.
Material Changes
No material financial changes versus a prior comparable period are detailed in this filing. The document solely references the issuance of a press release on May 20, 2018, which is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or a discussion of risks and contingencies within the body text. It notes that the press release (Exhibit 99.1) contains a quote from Dr. Toby Maher, but the content of that quote is not included in the provided text.
Key Facts for Investor Verification
- Verify the content of the attached press release (Exhibit 99.1) dated May 22, 2018, as this filing incorporates it by reference.
- Confirm the registrant name is Galapagos NV, as the metadata reference to "Lakefront Biotherapeutics NV" appears to be incorrect based on the filing text.
- Note that this filing does not contain standalone financial data; investors must refer to the incorporated press release or other periodic reports for financial metrics.